Our prior conclusions reflect that DDR2 may constitute an alternative therapeutic target, especially for those individuals with invasive BC or with a high risk of relapse, due to the ineffectiveness of hormone and HER-2 therapies, like in triple-negative subtype, as well as the development of chemoresistance. The gene discussed is ERBB2; the disease is breast cancer.